

UCLA

UCLA Previously Published Works

Title

Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease

Permalink

<https://escholarship.org/uc/item/9bq0k1c9>

Authors

Ma, Qiu-Lan
Teng, Edmond
Zuo, Xiaohong
et al.

Publication Date

2018-06-01

DOI

10.1016/j.nbd.2018.02.014

Peer reviewed



Published in final edited form as:

Neurobiol Dis. 2018 June ; 114: 120–128. doi:10.1016/j.nbd.2018.02.014.

Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease

Qiu-Lan Ma^{a,b,*}, Edmond Teng^{a,b}, Xiaohong Zuo^{a,b}, Mychica Jones^{a,b}, Bruce Teter^{a,b}, Evan Y. Zhao^{a,b}, Cansheng Zhu^{a,c}, Tina Bilousova^d, Karen H. Gylys^d, Liana G. Apostolova^e, Mary Jo LaDu^f, Mir Ahamed Hossain^g, Sally A. Frautschy^{a,b}, Gregory M. Cole^{a,b,*}

^aDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, United States

^bVeterans Affairs Greater Los Angeles Healthcare System, United States

^cDepartment of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

^dSchool of Nursing, University of California, Los Angeles, United States

^eDepartments of Neurology, Radiology, and Medical and Molecular Genetics, Indiana University School of Medicine, United States

^fDepartment of Anatomy and Cell Biology, University of Illinois at Chicago, United States

^gThe Johns Hopkins University School of Medicine, The Kennedy Krieger Institute, United States

Abstract

Synaptic neurodegeneration is thought to be an early event initiated by soluble β -amyloid ($A\beta$) aggregates that closely correlates with cognitive decline in Alzheimer disease (AD). Apolipoprotein $\epsilon 4$ (*APOE4*) is the most common genetic risk factor for both familial AD (FAD) and sporadic AD; it accelerates $A\beta$ aggregation and selectively impairs glutamate receptor function and synaptic plasticity. However, its molecular mechanisms remain elusive and these synaptic deficits are difficult to monitor. AD- and *APOE4*-dependent plasma biomarkers have been proposed, but synapse-related plasma biomarkers are lacking. We evaluated neuronal pentraxin 1 (NP1), a potential CNS-derived plasma biomarker of excitatory synaptic pathology. NP1 is preferentially expressed in brain and involved in glutamate receptor internalization. NP1 is secreted presynaptically induced by $A\beta$ oligomers, and implicated in excitatory synaptic and mitochondrial deficits. Levels of NP1 and its fragments were increased in a correlated fashion in both brain and plasma of 7–8 month-old E4FAD mice relative to E3FAD mice. NP1 was also found in exosome preparations and reduced by dietary DHA supplementation. Plasma NP1 was higher in E4FAD+ (*APOE4*^{+/+}/*FAD*^{+/-}) relative to E4FAD- (non-carrier; *APOE4*^{+/+}/*FAD*^{-/-}) mice, suggesting NP1 is modulated by $A\beta$ expression. Finally, relative to normal elderly, plasma

*Corresponding authors at: Mary S. Easton Translational Center, Veterans Greater Los Angeles Healthcare, 11301 Wilshire Blvd. Bldg 114, Room 114-3, Los Angeles, CA 90073, United States. QiulanMa@mednet.ucla.edu (Q.-L. Ma), GregoryCole@mednet.ucla.edu (G.M. Cole).

Conflicts of interest
None.

NP1 was also elevated in patients with mild cognitive impairment (MCI) and elevated further in the subset who progressed to early-stage AD. In those patients, there was a trend towards increased NP1 levels in *APOE4* carriers relative to non-carriers. These findings indicate that NP1 may represent a potential synapse-derived plasma biomarker relevant to early alterations in excitatory synapses in MCI and early-stage AD.

Keywords

Alzheimer disease; β -amyloid; Plasma biomarkers; Neuronal pentraxin 1; APOE; MCI; Dementia; EFAD mice

1. Introduction

Synaptic degeneration is one of the earliest pathological hallmarks of Alzheimer disease (AD). Synapse loss, not A β burden, is the major correlate of cognitive impairment and disease progression (Terry et al., 1991). Thus therapeutic strategies for AD should include synapse-protective interventions (Shankar et al., 2007) but synaptic degeneration cannot be directly monitored. Overwhelming evidence supports the idea that soluble oligomeric A β (oA β) represents the major A β toxic species that contributes to early synaptic and cognitive deficits in AD (Ma et al., 2006; Shankar et al., 2007; Gong and Iqbal, 2008; Tomic et al., 2009; Danysz and Parsons, 2012; Ma et al., 2013), involving both NMDA receptor dysregulation (Guntupalli et al., 2016) and NMDA receptor-induced excitotoxicity (Snyder et al., 2005; Shankar et al., 2007; Li et al., 2011).

The APOE4 allele is the most common genetic risk factor for AD. It increases AD risk by 4–15 fold and is present in more than half of all patients with MCI or dementia due to AD (Bu, 2009; Hua et al., 2011). Human *APOE4* accelerates amyloid deposition, reduces amyloid clearance and glucose uptake, and stabilizes oA β . Since clinical symptoms of AD only emerge after apparently irreversible neurological degeneration, early interventions in high-risk *APOE4* carriers may require early diagnostic and surrogate biomarkers. ApoE4 increases the oligomerization of A β (Hashimoto et al., 2012) and the concentrations of oA β within the interstitial fluid (Hudry et al., 2013), co-localizes with oA β , and enhances synaptic oA β localization (Koffie et al., 2012). However, we lack A β - and/or apoE4-regulated synapse-derived blood biomarkers for clinical studies.

ApoE4 also appears to modulate cerebral metabolism independently of its effects on A β deposition (Jagust et al., 2012), as regional reductions in fluorodeoxyglucose-positron emission tomography (FDG-PET) signaling can be seen in younger *APOE4* carriers several decades prior to A β deposition and the possible onset of dementia (Reiman et al., 2004). This may be a direct consequence of apoE4-mediated synaptic deficits, which include downregulation of synaptic mitochondrial proteins (Shi et al., 2014) and dendritic spines (Dumanis et al., 2009). The selective effects of apoE4 (versus apoE3) on mitochondria and excitatory synapses could be related to APOER2/reelin receptor control of AMPA and NMDA receptor surface activity (Chen et al., 2010).

Neuronal pentraxin 1 (NP1) and its receptor (NPR) are primarily expressed in excitatory neurons, where NPR is involved in the function of AMPA receptors at the synapse (Schlimgen et al., 1995; Cho et al., 2008) including GluA1 (Lee et al., 2017). NP1 negatively regulates mitochondrial function, transport and caspase activation through the intrinsic program of apoptosis pathway (Clayton et al., 2012) and negatively regulates excitatory synapse density (Figueiro-Silva et al., 2015). Since the expression of neuronal pentraxins is disrupted in AD brain and AD animal models (Abad et al., 2006; Bilousova et al., 2015; Cummings et al., 2017; Neuner et al., 2017), we investigated whether NP1 might serve as excitatory synapse derived plasma biomarker that is related to A β and/or apoE isoform effects.

2. Materials and methods

2.1. Reagents and antibodies

All chemical reagents were purchased from Sigma-Aldrich, unless otherwise stated. Immunohistochemical and biochemical analyses utilized mouse monoclonal antibodies to Alix (Cell Signaling Technology Cat# 2171S, RRID:AB_2299455), A β (6E10, Covance Research Products Inc. Cat# SIG-39320-200, RRID:AB_662798), drebrin (MBL International Cat# D029-3, RRID:AB_591275), PSD-95 (UC Davis/NIH NeuroMab Facility Cat# 75-028, RRID:AB_2307331), rabbit polyclonal antibodies to NP1 (Abgent Cat# AP7272c, RRID:AB_2236168) and A β (DAE, home-made (Lim et al., 2001)). Thromboplastin D was obtained from ThermoFisher (Middletown, VA). Recombinant NP1 was obtained from GenScript (Piscataway, NJ).

2.2. Experimental animals

All animal procedures were approved by the Institutional Animal Care Use Committee of the Greater Los Angeles VA Healthcare System. EFAD transgenic (Tg) mice expressing 5 familial AD (FAD) mutations (Oakley et al., 2006) with human (h) APOE3 (E3FAD) or hAPOE4 (E4FAD), specifically 5xFAD^{+/-}/APOE^{+/+}, were used for this study, as well as EFAD- (non-carrier; APOE4^{+/+}/FAD^{-/-}) mice (Oakley et al., 2006). The EFAD mice were developed by Dr. Mary Jo LaDu (Department of Anatomy and Cell Biology, University of Illinois at Chicago).

The effects of A β on brain NP1 levels were also examined in wild-type (WT) B6129SF2 mice. At 4 months of age, these mice were implanted with intracerebroventricular (icv) pumps containing a solution of A β 42 oligomers (released at 50 ng/h) and human HDL (37 μ g/h, Calbiochem, CA; for A β oligomer stabilization) or HDL alone as previously described (Frautschy et al., 2001; Begum et al., 2008). All animals were infused for 2 weeks.

Laboratory mice were maintained on two basic diets. A standard breeder chow base diet (Mouse Diet PMI 5015, LabDiet) containing 11% fat and 0.18% omega-3 fatty acid as alpha linolenic acid was fed to EFAD, EFAD-, and WT mice that were used to characterize NP1 levels in brain, plasma, and plasma exosomes. Prior work suggests that excitatory synaptic marker loss and caspase activation are sensitive to dietary docosahexaenoic acid (DHA) supplementation (Calon et al., 2004; Calon et al., 2005). Therefore, separate cohorts of

EFAD mice were assigned custom diets from 3 to 7 months of age: a DHA-depleting base diet containing 5% fat with high n-6 linoleic acid with or without DHA supplementation (Calon et al., 2004). These mice were divided into 4 treatment groups; E3FAD and E4FAD mice were fed the high n-6 polyunsaturated fatty acid (PUFA) diet either with or without 0.6% DHA (D; DHASCO oil, Martek, Columbia, MD).

2.3. Tissue preparation

At the conclusion of all experiments, mice were anesthetized with a lethal dose of pentobarbital (100 mg/kg) and perfused with a phosphate buffer with protease and phosphatase inhibitors as previously described (Calon et al., 2005). Brains were removed and one hemisphere was post-fixed in a formalin solution, sectioned by cryostat, and then used for immunohistochemical analyses. The other hemisphere was dissected and the hippocampal region was snap frozen in liquid nitrogen for subsequent biochemical analyses.

2.4. Exosome preparation

We used ultracentrifugation methods to prepare plasma exosome fractions. Plasma exosomes were isolated per published protocol. Briefly, plasma was diluted 1:5 with PBS containing protease and phosphatase inhibitors [PhosSTOP and complete (Roche Diagnostics, Indianapolis IN)], and then sequentially spun at $300 \times g$ for 10 min at 4 °C, $2000 \times g$ for 10 min at 4 °C, and $10,000 \times g$ for 30 min at 4 °C to remove cells and debris. The resulting supernatant was then centrifuged at $100,000 \times g$ for 2h at 4 °C. The exosome pellet was subsequently resuspended in PBS with protease/phosphatase inhibitors prior to being snap frozen.

2.5. Western blotting

Mouse hippocampal tissue was extracted into two fractions. Samples were initially sonicated in Tris-buffered saline (TBS) then centrifuged at $100,000 \times g$ for 20 min at 4 °C. The resulting supernatant represents the soluble-cytosol (TBS) fraction. The remaining pellets were then sonicated in immunoprecipitation lysis buffer containing 1% Triton X-100, 0.5% sodium deoxycholate, and 0.5% SDS and re-centrifuged at $100,000 \times g$ for 20 min at 4 °C. This supernatant represents the membrano-cytoskeletal (lysis) fraction. Both the TBS and lysis buffers included protease and phosphatase inhibitors as previously described to prevent proteolysis and dephosphorylation of the tissue samples (Calon et al., 2004). For Western immunoblotting (WB), protein concentrations were determined using the Bio-Rad DC protein assay. Each sample contained 30 µg of protein and was boiled in Laemmli sample buffer for 3 min prior to being loaded into a 34 lane 7–20% Tris-glycine gradient gel. Gels were electrophoresed, then transferred to Immobilon-P PVDF membranes (Millipore, Bedford, MA) as previously described (Ma et al., 2006). Blots were developed in the linear range with chemiluminescent detection and relative optical density on film scanned with a Biorad densitometer (Calon et al., 2004).

2.6. NP1 ELISA

Plasma NP1 levels were measured using a commercial ELISA kit (Aviva System Biology; human, OKDD0433, San Diego, CA) per the manufacturer's recommended protocol. Briefly,

100 μ l of serially titrated NP1 standards and two times diluted plasma samples were added into wells of the Anti-NP1 pre-coated micro-well plate. Two replicates of each standard and sample were used for the assay. The plate was incubated at RT for 2 h on a shaker plate. After washing with TBS, 100 μ l of biotinylated mouse anti-NP1 detector antibody was added and incubated at RT for 1 h. Then, 100 μ l of Avidin-HRP conjugate was added and incubated for 1 h. After washing with TBS, 90 μ l of TMB substrate was added and incubated for 20 min, then 50 μ l of stop solution was added and the absorbance was measured at 450 nm. Plasma NP1 concentrations were then calculated from the standard curve. The % of CV cutoff was above 10%, we excluded samples with CV's > 10% for data analysis.

2.7. Human plasma

Human plasma samples from APOE-genotyped cognitively normal elderly (NC, $n = 31$) and patients with mild cognitive impairment (MCI, $n = 33$) were obtained from the ImaGene Study (Ramirez et al., 2016) conducted through the UCLA Easton Alzheimer Center. Over three years of longitudinal follow-up during this study, a subset of MCI subjects subsequently progressed to probable mild AD dementia (EAD; $n = 11$); the remainder continued to meet diagnostic criteria for MCI (MCI; $n = 22$).

2.8. Statistical analysis

Analyses of biochemical and immunohistochemical data were performed using StatView 5.0 software. Group differences were compared using *t*-tests or analysis of variance (ANOVA). Post-hoc comparisons were performed using Fisher LSD where appropriate.

3. Results

3.1. Plasma levels of NP1 and its fragments were increased in E4FAD mice and responded to DHA treatment

WB data for plasma levels of NP1 and its associated fragments are shown in Fig. 1. The two primary NP1 species identified by WB in EFAD mouse plasma were a full-length band at ~50 kDa and a shorter fragment at ~38 kDa (Fig. 1A, center lane). While both of these bands were also seen in the lane loaded with recombinant NP1 protein (Fig. 1A, left lane), they were not seen in plasma from NP1 knockout mice (Fig. 1A, right lane; gift from M. A. Hossein, Kennedy Krieger Institute, Johns Hopkins University), suggesting that the ~50 kDa and ~38 kDa bands visualized on WB are NP1 specific.

A representative WB for NP1 in plasma samples from 7–8-month-old E4FAD and E3FAD mice is shown in Fig. 1B. Quantitative analyses indicated that E4FAD mice had significantly higher levels of both full-length NP1 (Fig. 1B; $p < 0.001$) and the ~38 kDa NP1 fragment (Fig. 1C; $p < 0.01$) than E3FAD mice. Plasma levels of the ~50 kDa and ~38 kDa NP1 species were closely correlated (Fig. 1D; $r_2 = 0.795$, $p < 0.001$).

Prior work from our group has also shown that dietary DHA supplementation ameliorates excitatory synaptic pathology in Tg2576 mice (Calon et al., 2004; Calon et al., 2005). Since plasma NP1 species represent potential peripheral biomarkers of synaptic dysfunction, we examined the effects of DHA supplementation on these markers in E3FAD and E4FAD

mice. E4FAD mice maintained on the DHA-supplemented diet from 3 to 7–8 months of age had significantly lower levels of full-length NP1 (Fig. 1B; $p < 0.01$) and the ~38 kDa NP1 fragment (Fig. 1C; $p < 0.05$) relative to E4FAD mice maintained on the DHA-depleted diet. Plasma levels of each of these markers in DHA-supplemented E4FAD mice approximated those seen in E3FAD mice.

3.2. Hippocampal NP1 levels were increased in E4FAD mice and responded to DHA treatment

We subsequently sought to determine whether these observed changes in the levels plasma NP1 species reflected changes in hippocampal NP1 expression. WB data for NP1 levels in E3FAD and E4FAD hippocampus are shown in Fig. 2. Full length NP1 levels were numerically higher in E4FAD versus E3FAD mice, but this difference fell short of statistical significance (Fig. 2A; $p = 0.098$). Significantly higher levels of the ~38 kDa NP1 fragment were seen in E4FAD versus E3FAD mice (Fig. 2B; $p < 0.01$). Dietary DHA supplementation treatment in E4FAD mice significantly reduced both the full-length (Fig. 2A; $p < 0.05$) and ~38 kDa (Fig. 2B; $p < 0.01$) NP1 species to levels comparable to those seen in the E3FAD mice. Furthermore, across all E4FAD animals, hippocampal levels of full-length NP1 were significantly correlated with plasma levels of both the full-length (Fig. 2C; $r^2 = 0.538$, $p = 0.002$) and ~38 kDa (Fig. 2D; $r^2 = 0.269$, $p = 0.048$) NP1 species.

3.3. Elevations of plasma and brain NP1 levels in E4FAD mice were FAD transgene dependent

We subsequent sought to determine the relative effects of APOE4 expression and A β overproduction on plasma and brain NP1 levels. Fig. 3 illustrates relative plasma NP1 levels in E4FAD and E4FAD-mice. While differences in plasma levels of full-length NP1 between E4FAD and E4FAD-mice failed to reach statistical significance (Fig. 3A; $p > 0.05$), the E4FAD mice had significantly higher plasma levels of the 38 kDa NP1 fragment (Fig. 3B; $p = 0.05$). Immunohistochemical analyses were used to compare brain NP1 expression between E4FAD and E4FAD-mice (Fig. 4). Confocal imaging in 7-month-old mice demonstrated increased cortical NP1 expression in E4FAD mice relative to E4FAD-mice (Fig. 4A). Likewise, hippocampal NP1 levels were significantly higher in E4FAD mice (Fig. 4B and C; $p < 0.001$). Taken together these data suggest that both APOE genotype and A β overproduction may contribute to increased central and peripheral NP1 levels.

3.4. A β 42 oligomer infusions increased brain NP1 expression in wild type mice

Since the mutant APP and PS1 transgenes that are overexpressed in EFAD mice may have effects beyond A β overproduction, we sought to confirm the effects of A β on brain NP1 expression using icv infusions in wild type (WT) mice. A β was infused as a solution of A β 42 oligomers (oA β), which represent an important toxic A β species that contributes to synaptic and cognitive deficits (Gong and Iqbal, 2008; Danysz and Parsons, 2012; Ma et al., 2013). Fig. 5 shows representative hippocampal A β and NP1 staining after 2 weeks of oA β or vehicle infusion into the right ventricles of 4-month-old WT mice. Infusions of oA β increased deposition of both A β (Fig. 5A) and NP1 (Fig. 5B). These results confirm prior work in neuronal cell culture indicating that A β can induce NP1 expression (Abad et al., 2006).

3.5. Plasma NP1 levels were elevated in patients with mild cognitive impairment (MCI) and in cases of early-stage AD that had progressed from MCI (EAD)

Previous work has indicated that brain NP1 levels are increased in both APP/PS1 mice and human patients with sporadic late-onset AD (Abad et al., 2006). Therefore, we examined whether the plasma NP1 elevations seen in E4FAD mice would be detectable in human plasma samples. Because NP1 is enriched in excitatory synapses that are lost with AD progression (Mota et al., 2014) and transgenic rodent models of AD are thought to represent very early stages of disease progression (Ashe, 2005), we focused on plasma samples from MCI, including those that subsequently progressed to mild AD dementia, and age-matched cognitively normal elderly (NC). Sandwich ELISA analysis of plasma NP1 demonstrated significantly higher levels in patients with MCI ($p < 0.05$, Fig. 6A) and even higher levels in early-stage AD ($p < 0.001$, Fig. 6A) relative to age-matched cognitively normal elderly. In our small early AD subgroup, NP1 also showed a trend for an increase in *APOE4* carriers compared to *APOE4* non-carriers ($p = 0.078$, Fig. 6B). While these results require confirmation with a much larger sample, they support the hypothesis that increased plasma NP1 levels may reflect early excitatory synapse loss in MCI and early AD, and are modulated by the *APOE4* genotype with progressive disease.

3.6. Plasma NP1 was enriched in plasma exosome fractions from E4FAD mice

It remains uncertain how synapse-specific proteins such as NP1 are transported from the brain to the plasma. One potential mechanism is via exosomes. Prior work has shown that NP1 is present in human CSF exosome-enriched extracellular vesicles (EVs) (Chiasserini et al., 2014). We investigated whether NP1 is present in plasma EVs. EVs were isolated from pooled plasma of E4FAD mice and probed by WB for NP1 (Fig. 7). We compared two independent pooled plasma samples from E4FAD mice ($n = 4/\text{group}$). Fig. 7 demonstrates the relative enrichment of NP1 in plasma EV fractions (which contain the exosome marker ALIX) relative to whole plasma and post-ultracentrifugation supernatant fractions. These results suggest that NP1 may be exported from brain via exosomes or other extracellular vesicles, though we cannot rule out the possibility that NP1 may merely represent a contaminant within exosome-enriched fractions.

4. Discussion

The purpose of this study was to determine whether brain and/or plasma levels of NP1 reflect A β - and *APOE4*-associated synaptic deficits in animal models of AD, as well as in MCI and probable AD dementia cases. In the experiments described above, we demonstrate that the expression of both full length NP1 (~50 kDa) and a 38 kDa NP1 fragment were increased in a correlated fashion between hippocampal and plasma samples from E4FAD mice compared to E3FAD mice. Brain and plasma NP1 levels appear to reflect treatable synaptic dysfunction, as dietary DHA supplementation resulted in increased expression of excitatory synaptic markers and decreased expression of NP1 in E4FAD mice. As suggested by prior work (Abad et al., 2006), increased plasma and brain NP1 levels appear to be mediated in part through increased A β expression. Furthermore, plasma NP1 levels were also increased in patients with MCI (particularly those who subsequently progressed to AD dementia) relative to cognitively normal elderly. Within the small progressive MCI

subgroup, NP1 levels were marginally higher in *APOE4* carriers relative to non-carriers. Taken together, these data indicate that plasma NP1 species may serve as potential A β and *APOE4*-dependent biomarkers of early synaptic dysfunction in AD. Although the precise mechanism by which these NP1 species reach the plasma remains uncertain, they may be trafficked from the brain via extracellular vesicles, possibly exosomes, after endocytosis and processing.

NP1 is one of a family of neuronal pentraxins (NPs) that appear to play important roles in both synaptic remodeling and neuronal apoptosis. NP1 is predominantly expressed in neurons at high concentrations in the hippocampus, cerebellum, and cerebral cortex (Schlimgen et al., 1995). NP1 is enriched at excitatory synapses and functions closely associated with NP2 (Narp) and AMPARs. NP1 interacts with the N-terminal domain of the AMPA receptor GluA4 subunit to mediate GluA4 synaptic recruitment (Sia et al., 2007). NP1 and NP2 form heterocomplexes that are required in vivo for the normal development of AMPAR-mediated transmission and function in developmental and activity-dependent synaptic plasticity (Xu et al., 2003; Sia et al., 2007; Koch and Ullian, 2010). NPR and NP1 interact directly with GluA1 and increase GluA1 currents and puncta intensity; this adds support to a model in which NPR recruits and stabilizes NP1 and NP2 on the presynaptic plasma membrane where NPR acts in excitatory synapse assembly by binding to the N-terminal domain of AMPARs (Lee et al., 2017). Moreover, NP1 regulates the surface expression of the Kv7.2 subunit of the Kv7 family of potassium channels that control neuronal excitability (Figueiro-Silva et al., 2015). In mature neurons, NP1 negatively regulates excitatory density and synaptic plasticity (Figueiro-Silva et al., 2015), a process known to be A β oligomer sensitive (Guntupalli et al., 2016). Elevations in NP1 can be seen in a number of pro-apoptotic conditions (DeGregorio-Rocasolano et al., 2001; Hossain et al., 2004; Enguita et al., 2005) and contribute to mitochondrial damage and neuronal death (Clayton et al., 2012; Al Rahim et al., 2013).

Prior work suggests that NP1 facilitates neurodegeneration in AD, as its expression is increased in dystrophic neurites around plaques in postmortem AD brain and in transgenic AD mice (Abad et al., 2006; Cummings et al., 2017; Neuner et al., 2017). Cell culture studies suggest that A β -associated neuronal apoptosis is mediated through GSK-3 β induced increases in NP1 expression (Abad et al., 2006; Russell et al., 2011). Our findings that NP1 levels were significantly higher in the brain of E4FAD mice relative to E4FAD-mice, and in WT mice infused with A β 42 relative to vehicle, confirm the relationship between A β and NP1 and raise the possibility that plasma NP1 levels reflect the downstream effects of cerebral A β neurotoxicity. In human study, we found plasma NP1 levels were significantly elevated in MCI and early AD, suggesting that the alteration of CSF and/or plasma NP1 might be independent on NP2 and also disease-stage dependent reflecting synaptic pathology. Less NP1 elevation observed in AD or later stages of AD might be caused by extensive loss of its synaptic sources (Llano et al., 2017; Brinkmalm et al., 2018).

In our study with a small subgroup, we found that plasma NP1 had a trend increase in the subjects with *APOE4* carriers who had recently progressed from MCI to AD dementia. Similarly, our animal study shows higher brain and plasma NP1 levels in E4FAD versus E3FAD mice. These data suggesting that *APOE4*-associated synaptic dysfunction (Klein et

al., 2010) may closely link to NP1 dysfunction. The *APOE* ϵ 4 allele is the major genetic risk factor for the late onset AD (Corder et al., 1993; Kim et al., 2009). While some of this increased risk appears to be mediated through A β -associated mechanisms (Christensen et al., 2010; Hashimoto et al., 2012; Koffie et al., 2012), other *APOE4*-associated effects on dendritic spine density and morphology (Dumanis et al., 2009; Klein et al., 2010), glutamate receptor function and reelin-induced enhancement of long-term potentiation (Chen et al., 2010) appear to be independent of (and synergistic with) A β pathophysiology. Prior work with *EFAD*-mice has shown impaired synaptic plasticity (Trommer et al., 2004) and decreased expression of synaptic markers such as drebrin (Nwabuisi-Heath et al., 2014) in *APOE4*-TR versus *APOE3*-TR animals.

Prior work from our group and others has demonstrated that DHA supplementation protects against A β -associated depletion of synaptic markers such as drebrin, NR2B and PSD-95 in Tg2576 mice (Calon et al., 2004; Calon et al., 2005) and drebrin in APPsw/PS1 E9 mice (Perez et al., 2010). DHA supplementation in the current study in E4FAD mice showed reduced brain and plasma levels of NP1 species. While DHA treatment has not been shown to improve outcomes in mild-to-moderate AD dementia patients who carry an *APOE4* allele (Quinn et al., 2010), it does appear to have beneficial effects on MCI (Sinn et al., 2012; Lee et al., 2013; Bo et al., 2017). Furthermore, recent data indicate that increased consumption of seafood (which has high DHA levels) is associated with decreased AD neuropathology in *APOE4* carriers (Morris et al., 2016).

Although it remains uncertain how NP1 may be transported from brain to plasma, we observed that NP1 (both full length and a 38 kDa fragment) were found in plasma exosome enriched fractions in animals. This is consistent with the presence of NP1 peptides in extracellular vesicle (EV)/exosome fractions isolated from pooled samples of human CSF (Chiasserini et al., 2014). Exosomes are small vesicles derived from the multivesicular bodies (MVBs) of the endocytic pathways that can cross the blood-brain barrier (Zhuang et al., 2011; Kalani et al., 2014; Andras and Toborek, 2016). Since NP1 interacts with AMPA-type glutamate receptors that participate in excitatory synaptic transmission involved in learning and memory, and neural exosomes contain GluR2/3 subunits of glutamate receptors (Faure et al., 2006), the detection NP1 species in exosome-enriched plasma fractions may reflect alterations in AMPA receptor function or expression during early stages of AD pathophysiology. The independently regulated NP2 is also found in plasma neural exosomes where it was recently reported to be decreased in AD along with GluA4 (Goetzl et al., 2018).

However, there are a number of limitations to using plasma NP1 as a specific biomarker for AD. First, hypoxic-ischemic injury can induce NP1 expression (Hossain et al., 2004). Second, although NP1 is thought to be exclusively expressed in brain and was not detected in heart, skeletal muscle, placenta, lung, liver, pancreas, or kidney samples from humans, rats, and mice (Hsu and Perin, 1995; Omeis et al., 1996), it remains possible that a portion of the NP1 found in plasma might be derived from heretofore unexamined peripheral sources. Third, only a small subgroup of human MCI patients progressed to mild AD dementia represents. While there was a trend towards higher plasma NP1 levels amongst *APOE4*

carriers versus non-carriers in this subgroup, this finding needs to be validated with a much larger sample size.

5. Conclusion

We found that NP1 species were significantly increased in both plasma and brain samples of E4FAD mice in a correlated fashion. NP1 species were also increased in human plasma samples from patients diagnosed with MCI (particularly those who subsequently progressed to AD dementia) relative to cognitively normal elderly. These elevations of NP1 at earlier stages of AD pathophysiology may parallel the process of synapse loss. In E4FAD mice, these increases in NP1 were ameliorated by dietary DHA supplementation. Since NP1 may be involved in progressive excitatory synapse loss associated with A β and APOE4, our findings suggest that NP1 may represent a potential plasma biomarker for excitatory synaptic dysfunction in MCI and early AD, which could be used to monitor disease progression and/or response to therapeutic interventions.

Acknowledgments

This work was supported by State of California Department of Public Health Alzheimer's Disease Program (RFA #16-10054, QLM), VA MERIT (BX000542, GMC), NIH RO1 (AT008916, GMC), NIH RO1 (AG13471, GMC), NIH R21 (AG050269, SAF), R01 AG040770 (LGA), K02 AG048240 (LGA), P50 AG16570 and philanthropic support for the Easton Consortium for AD Drug Discovery and Biomarker Development (LGA and GMC).

References

- Abad MA, Enguita M, DeGregorio-Rocasolano N, Ferrer I, Trullas R, 2006. Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is overexpressed in dystrophic neurites in Alzheimer's brain. *J. Neurosci* 26, 12735–12747. [PubMed: 17151277]
- Al Rahim M, Thatipamula S, Hossain MA, 2013. Critical role of neuronal pentraxin 1 in mitochondria-mediated hypoxic-ischemic neuronal injury. *Neurobiol. Dis* 50, 59–68. [PubMed: 23069675]
- Andras IE, Toborek M, 2016. Extracellular vesicles of the blood-brain barrier. *Tissue Barriers* 4, e1131804. [PubMed: 27141419]
- Ashe KH, 2005. Mechanisms of memory loss in Abeta and tau mouse models. *Biochem. Soc. Trans* 33, 591–594. [PubMed: 16042551]
- Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA, 2008. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. *J. Pharmacol. Exp. Ther* 326, 196–208. [PubMed: 18417733]
- Bilousova T, Taylor K, Emirzian A, Gylys R, Frautschy SA, Cole GM, Teng E, 2015. Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease. *Neurobiol. Dis* 74, 32–40. [PubMed: 25449907]
- Bo Y, Zhang X, Wang Y, You J, Cui H, Zhu Y, Pang W, Liu W, Jiang Y, Lu Q, 2017. The n-3 polyunsaturated fatty acids supplementation improved the cognitive function in the Chinese elderly with mild cognitive impairment: a double-blind randomized controlled trial. *Nutrients* 9.
- Brinkmalm G, Sjodin S, Simonsen AH, Hasselbalch SG, Zetterberg H, Brinkmalm A, Blennow K, 2018. A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for Alzheimer's disease. *Proteomics Clin. Appl* 12.
- Bu G, 2009. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nat. Rev. Neurosci* 10, 333–344. [PubMed: 19339974]

- Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubada O, Rostaing P, Triller A, Salem N Jr., Ashe KH, Frautschy SA, Cole GM, 2004. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. *Neuron* 43, 633–645. [PubMed: 15339646]
- Calon F, Lim GP, Morihara T, Yang F, Ubada O, Salem N Jr., Frautschy SA, Cole GM, 2005. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. *Eur. J. Neurosci* 22, 617–626. [PubMed: 16101743]
- Chen Y, Durakogluligil MS, Xian X, Herz J, 2010. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. *Proc. Natl. Acad. Sci. U. S. A* 107, 12011–12016. [PubMed: 20547867]
- Chiasserini D, van Weering JR, Piersma SR, Pham TV, Malekzadeh A, Teunissen CE, de Wit H, Jimenez CR, 2014. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. *J. Proteome* 106, 191–204.
- Cho RW, Park JM, Wolff SB, Xu D, Hopf C, Kim JA, Reddy RC, Petralia RS, Perin MS, Linden DJ, Worley PF, 2008. mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE. *Neuron* 57, 858–871. [PubMed: 18367087]
- Christensen DZ, Schneider-Axmann T, Lucassen PJ, Bayer TA, Wirths O, 2010. Accumulation of intraneuronal Aβ correlates with ApoE4 genotype. *Acta Neuropathol.* 119, 555–566. [PubMed: 20217101]
- Clayton KB, Podlesniy P, Figueiro-Silva J, Lopez-Domenech G, Benitez L, Enguita M, Abad MA, Soriano E, Trullas R, 2012. NP1 regulates neuronal activity-dependent accumulation of BAX in mitochondria and mitochondrial dynamics. *J. Neurosci* 32, 1453–1466. [PubMed: 22279230]
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261, 921–923. [PubMed: 8346443]
- Cummings DM, Benway TA, Ho H, Tedoldi A, Fernandes Freitas MM, Shahab L, Murray CE, Richard-Loendt A, Brandner S, Lashley T, Salih DA, Edwards FA, 2017. Neuronal and peripheral pentraxins modify glutamate release and may interact in blood-brain barrier failure. *Cereb. Cortex* 27, 3437–3448. [PubMed: 28334103]
- Danzysz W, Parsons CG, 2012. Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine—searching for the connections. *Br. J. Pharmacol* 167, 324–352. [PubMed: 22646481]
- DeGregorio-Rocasolano N, Gasull T, Trullas R, 2001. Overexpression of neuronal pentraxin 1 is involved in neuronal death evoked by low K(+) in cerebellar granule cells. *J. Biol. Chem* 276, 796–803. [PubMed: 11031272]
- Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, Weeber EJ, Turner RS, Xu B, Rebeck GW, Hoe HS, 2009. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. *J. Neurosci* 29, 15317–15322. [PubMed: 19955384]
- Enguita M, DeGregorio-Rocasolano N, Abad A, Trullas R, 2005. Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. *Mol. Pharmacol* 67, 1237–1246. [PubMed: 15630079]
- Faure J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J, Sadoul R, 2006. Exosomes are released by cultured cortical neurones. *Mol. Cell. Neurosci* 31, 642–648. [PubMed: 16446100]
- Figueiro-Silva J, Gruart A, Clayton KB, Podlesniy P, Abad MA, Gasull X, Delgado-Garcia JM, Trullas R, 2015. Neuronal pentraxin 1 negatively regulates excitatory synapse density and synaptic plasticity. *J. Neurosci* 35, 5504–5521. [PubMed: 25855168]
- Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM, 2001. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. *Neurobiol. Aging* 22, 993–1005. [PubMed: 11755008]
- Goetzl EJ, Abner EL, Jicha GA, Kapogiannis D, Schwartz JB, 2018. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. *FASEB J.* 32, 888–893. [PubMed: 29025866]
- Gong CX, Iqbal K, 2008. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. *Curr. Med. Chem* 15, 2321–2328. [PubMed: 18855662]

- Guntupalli S, Widagdo J, Anggono V, 2016. Amyloid-beta-induced dysregulation of AMPA receptor trafficking. *Neural Plast.* 2016, 3204519. [PubMed: 27073700]
- Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT, 2012. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. *J. Neurosci* 32, 15181–15192. [PubMed: 23100439]
- Hossain MA, Russell JC, O'Brien R, Laterra J, 2004. Neuronal pentraxin 1: a novel mediator of hypoxic-ischemic injury in neonatal brain. *J. Neurosci* 24, 4187–4196. [PubMed: 15115814]
- Hsu YC, Perin MS, 1995. Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization. *Genomics* 28, 220–227. [PubMed: 8530029]
- Hua X, Gutman B, Boyle CP, Rajagopalan P, Leow AD, Yanovsky I, Kumar AR, Toga AW, Jack CR Jr., Schuff N, Alexander GE, Chen K, Reiman EM, Weiner MW, Thompson PM, Alzheimer's Disease Neuroimaging I, 2011. Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. *Neuroimage* 57, 5–14. [PubMed: 21320612]
- Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, Davidson BL, Hyman BT, 2013. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. *Sci. Transl. Med* 32, 1–12 (5:212ra161).
- Jagust WJ, Landau SM, Alzheimer's Disease Neuroimaging, I., 2012. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. *J. Neurosci* 32, 18227–18233. [PubMed: 23238736]
- Kalani A, Tyagi A, Tyagi N, 2014. Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. *Mol. Neurobiol* 49, 590–600. [PubMed: 23999871]
- Kim J, Basak JM, Holtzman DM, 2009. The role of apolipoprotein E in Alzheimer's disease. *Neuron* 63, 287–303. [PubMed: 19679070]
- Klein RC, Mace BE, Moore SD, Sullivan PM, 2010. Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. *Neuroscience* 171, 1265–1272. [PubMed: 20951774]
- Koch SM, Ullian EM, 2010. Neuronal pentraxins mediate silent synapse conversion in the developing visual system. *J. Neurosci* 30, 5404–5414. [PubMed: 20392962]
- Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL, 2012. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. *Brain* 135, 2155–2168. [PubMed: 22637583]
- Lee LK, Shahar S, Chin AV, Yusofif NA, 2013. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. *Psychopharmacology* 225, 605–612. [PubMed: 22932777]
- Lee SJ, Wei M, Zhang C, Maxeiner S, Pak C, Calado Botelho S, Trotter J, Sterky FH, Sudhof TC, 2017. Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses. *J. Neurosci* 37, 1062–1080. [PubMed: 27986928]
- Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ, 2011. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. *J. Neurosci* 31, 6627–6638. [PubMed: 21543591]
- Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM, 2001. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. *J. Neurosci* 21, 8370–8377. [PubMed: 11606625]
- Llano DA, Bundela S, Mudar RA, Devanarayan V, Alzheimer's Disease Neuroimaging I, 2017. A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. *PLoS One* 12, e0182098. [PubMed: 28771542]
- Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM, 2006. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. *J. Neurosci. Res* 83, 374–384. [PubMed: 16385556]

- Ma QL, Zuo X, Yang F, Ubada OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA, 2013. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. *J. Biol. Chem* 288, 4056–4065. [PubMed: 23264626]
- Morris MC, Brockman J, Schneider JA, Wang Y, Bennett DA, Tangney CC, van de Rest O, 2016. Association of seafood consumption, brain mercury level, and APOE epsilon4 status with brain neuropathology in older adults. *JAMA* 315, 489–497. [PubMed: 26836731]
- Mota SI, Ferreira IL, Rego AC, 2014. Dysfunctional synapse in Alzheimer's disease - a focus on NMDA receptors. *Neuropharmacology* 76 Pt A, 16–26. [PubMed: 23973316]
- Neuner SM, Wilmott LA, Hoffmann BR, Mozhui K, Kaczorowski CC, 2017. Hippocampal proteomics defines pathways associated with memory decline and resilience in normal aging and Alzheimer's disease mouse models. *Behav. Brain Res* 322, 288–298. [PubMed: 27265785]
- Nwabuisi-Heath E, Rebeck GW, Ladu MJ, Yu C, 2014. ApoE4 delays dendritic spine formation during neuron development and accelerates loss of mature spines in vitro. *ASN Neuro* 6, e00134. [PubMed: 24328732]
- Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R., Vassar R, 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J. Neurosci* 26, 10129–10140. [PubMed: 17021169]
- Omeis IA, Hsu YC, Perin MS, 1996. Mouse and human neuronal pentraxin 1 (NPTX1): conservation, genomic structure, and chromosomal localization. *Genomics* 36, 543–545. [PubMed: 8884281]
- Perez SE, Berg BM, Moore KA, He B, Counts SE, Fritz JJ, Hu YS, Lazarov O, Lah JJ, Mufson EJ, 2010. DHA diet reduces AD pathology in young APP^{swe}/PS1^{Delta E9} transgenic mice: possible gender effects. *J. Neurosci. Res* 88, 1026–1040. [PubMed: 19859965]
- Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr., Weiner M, Shinto L, Aisen PS, 2010. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* 304, 1903–1911. [PubMed: 21045096]
- Ramirez LM, Goukasian N, Porat S, Hwang KS, Eastman JA, Hurtz S, Wang B, Vang N, Sears R, Klein E, Coppola G, Apostolova LG, 2016. Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy. *Neurobiol. Aging* 39, 82–89. [PubMed: 26923404]
- Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J, 2004. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *Proc. Natl. Acad. Sci. U. S. A* 101, 284–289. [PubMed: 14688411]
- Russell JC, Kishimoto K, O'Driscoll C, Hossain MA, 2011. Neuronal pentraxin 1 induction in hypoxic-ischemic neuronal death is regulated via a glycogen synthase kinase-3alpha/beta dependent mechanism. *Cell. Signal* 23, 673–682. [PubMed: 21130869]
- Schlimgen AK, Helms JA, Vogel H, Perin MS, 1995. Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system. *Neuron* 14, 519–526. [PubMed: 7695898]
- Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL, 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J. Neurosci* 27, 2866–2875. [PubMed: 17360908]
- Shi L, Du X, Zhou H, Tao C, Liu Y, Meng F, Wu G, Xiong Y, Xia C, Wang Y, Bi G, Zhou JN, 2014. Cumulative effects of the ApoE genotype and gender on the synaptic proteome and oxidative stress in the mouse brain. *Int. J. Neuropsychopharmacol* 17, 1863–1879. [PubMed: 24810422]
- Sia GM, Beique JC, Rumbaugh G, Cho R, Worley PF, Huganir RL, 2007. Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. *Neuron* 55, 87–102. [PubMed: 17610819]
- Sinn N, Milte CM, Street SJ, Buckley JD, Coates AM, Petkov J, Howe PR, 2012. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. *Br. J. Nutr* 107, 1682–1693. [PubMed: 21929835]

- Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P, 2005. Regulation of NMDA receptor trafficking by amyloid-beta. *Nat. Neurosci* 8, 1051–1058. [PubMed: 16025111]
- Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R, 1991. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. *Ann. Neurol* 30, 572–580. [PubMed: 1789684]
- Tomic JL, Pensalfini A, Head E, Glabe CG, 2009. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. *Neurobiol. Dis* 35, 352–358. [PubMed: 19523517]
- Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Ye GL, Sotak M, Sullivan PM, Pasternak JF, LaDu MJ, 2004. ApoE isoform affects LTP in human targeted replacement mice. *Neuroreport* 15, 2655–2658. [PubMed: 15570172]
- Xu D, Hopf C, Reddy R, Cho RW, Guo L, Lanahan A, Petralia RS, Wenthold RJ, O'Brien RJ, Worley P, 2003. Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. *Neuron* 39, 513–528. [PubMed: 12895424]
- Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L, Miller D, Zhang HG, 2011. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. *Mol. Ther* 19, 1769–1779. [PubMed: 21915101]




Fig. 1. Plasma NP1 species are increased in E4FAD mice and reduced by dietary DHA supplementation.

A. Both 50 kDa NP1 band and 38 kDa NP1 reactive fragments were absent in NP1 KO mice plasma, mouse IgG control and secondary (2nd) antibody alone lanes, but present in the NP1 recombinant protein loading lane, suggesting that these are NP1 specific reactive bands. Western blot analysis showed that plasma 50 kDa NP1 ($p < 0.001$, B), a 38 kDa NP1 reactive fragment ($p < 0.01$, B, C) were significantly increased in 7–8 month-old E4FAD mice compared to age-matched E3FAD mice. After EFAD mice were treated by 0.6% DHA from 3 to 7–8 months, DHA significantly reduced 50 kDa ($p < 0.01$, B) and 38 kDa NP1 species ($p < 0.05$, C) in E4FAD mice, but not in E3FAD mice. D. The plasma 50 kDa NP1 and 38 kDa NP1 fragments were significantly correlated ($R^2 = 0.795$, $p < 0.0001$). Error bars represent + s.e.m. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$, one-way ANOVA test. In this figure, E3 indicates E3FAD mice and E4 indicates E4FAD mice. + D indicates DHA treated groups.




Fig. 2. Brain NP1 species, are increased in E4FAD mice and reduced by dietary DHA supplementation; brain and plasma NP1 levels are correlated in E4FAD mice.

A. Western blot analysis showed a trend to an increase in 50 kDa NP1 band ($p = 0.098$, NS) in E4FAD mice compared to E3FAD mice, while DHA treatment significantly reduced it in DHA-treated E4FAD mice compared to untreated E4FAD mice ($p < 0.05$). B. 38 kDa NP1 fragments were increased in E4FAD mice compared to E3FAD mice, ($p < 0.01$), while DHA treatment significantly reduced 38 kDa NP1 fragment in DHA-treated E4FAD mice compared to untreated E4FAD mice ($p < 0.01$). C. Brain 50 kDa NP1 significantly correlated with plasma 50 kDa NP1 in E4FAD mice ($R^2 = 0.538$, $p = 0.002$). D. Brain 50 kDa NP1 was also significantly correlated with plasma levels of the 38 kDa NP1 fragment in E4FAD mice ($R^2 = 0.269$, $p = 0.048$). In this figure, E3 indicates E3FAD mice and E4 indicates E4FAD mice. +D indicates DHA treated groups.




Fig. 3. The elevation of Plasma NP1 in E4FAD mice is FAD transgene dependent.

A. Western blot analysis showed no statistical significance differences in plasma 50 kDa NP1 band in E4FAD mice compared to E4FAD-mice ($p > 0.05$, with both on 5015 diet). B. Western blot analysis showed increases in plasma 38 kDa NP1 fragment in E4FAD mice compared to E4FAD-mice ($p = 0.05$).




Fig. 4. The elevation of brain NP1 in E4FAD mice is FAD transgene dependent.

A. Immunohistochemistry by confocal imaging revealed brain cortex NP1 was increased in 7-month-old E4FAD mice compared to age-matched E4FAD-mice. B, C Quantification of brain hippocampal NP1 from DAB staining indicated that NP1 was significantly increased in E4FAD mice compared to E4FAD-mice ($p < 0.0001$) (with both on 5015 diet).




Fig. 5. A β 42 oligomers infusion increases brain NP1.

After infusing 50 μ g of A β 42 oligomers (OA β) into right ventricle of 4-month-old wild type (WT) mice over 2 weeks, brain adjacent serial sections were used for A β and NP1 staining. A. A β Deposition (red) was observed by immunostaining with anti-A β antibody, DAE, in the dentate gyrus of the hippocampus in OA β -infused WT mice but not in the vehicle (Veh)-infused mice. B. NP1 (green) was increased in the dentate gyrus of the hippocampus in OA β -infused WT mice but not in the Veh-infused mice. Quantification of immunostained NP1 cells confirmed a significant difference between the two groups ($p < 0.001$).




Fig. 6. Plasma NP1 levels are increased in MCI and early AD dementia.

A. ELISA analysis showed that plasma NP1 was increased in patients with MCI ($p < 0.05$) and early AD (EAD, $p < 0.01$) relative to normal cognitive elderly (NC). B. In the EAD group, NP1 showed a trend increases in APOE4 carriers (E4+) relative to non-APOE4 carriers (E4-).




Fig. 7. Plasma NP1 and NP1 fragments are enriched in exosomes containing fractions isolated from pooled plasma of E4FAD mice.

Plasma extracellular vesicles were isolated from pooled plasma of human and E4FAD mice via ultracentrifugation. Western blot analysis revealed that NP1 species were enriched in E4FAD plasma exosome enriched fractions. Western blot results demonstrated levels of NP1 and NP1 fragments in plasma before ultracentrifugation (pla, whole plasma) were reduced or depleted in the supernatant (sup) after pelleting of exosomes (Exo) using ultracentrifugation in two independent pooled plasma groups of E4FAD mice ($n = 4$ /per group). NP1 and its fragments were enriched in the pellet extracellular vesicle fractions, which contain the exosome marker ALIX.